Giacomo M. Guidelli

MD, Rheumatologist, SIR & EMEUNET & SIRyoung member | @SIRyoung_IT | @reumahumanitas | Assistant of Rheumatology, Humanitas Research Hospital (Rozzano, Milan)

[Dott. Simone Parisi @Sim_Orizon]

At #EULAR2026 we presented our work OP071 on synovial biopsy–driven therapeutic stratification in #PsoriaticArthritis.
Our preliminary data suggest that CD117+ myeloid synovitis may support IL-17/IL-23 axis targeting in selected PsA patients.
#PsA #Rheumatology #PrecisionMedicine

[Roxana González @RoxOsler]

REPLENISH phase 3 in relapsing PMR: 🔹secukinumab 150/300 mg doubled 🔹sustained remission at Week 52 vs placebo ➡️ 40–41% vs 20%, p<0.001 🔹improved complete sustained remission ➡️25–28% vs 5%.
🔹GC-sparing effect, with no new safety signals. #EULAR2026 #PMR

[David Liew @drdavidliew]

The benefits of exercise has been proven for most rheumatic diseases, and there are lots of good reasons why

#ACR25 Brian Andonian @RheumNow

[Dr.Mukesh , MD , DM @dr_immuno29]

🧩 #ACR25 Highlight | Skin in the Game: Cutaneous Clues in Rheumatic Disease
By Dr. Katharina S. Shaw, Penn Medicine

🧵 Post 1 | Eosinophilic Fasciitis vs Systemic Sclerosis
• 💡 Check distal digits → tightening absent in EF, universal in SSc
• ✴️ Groove sign & “pseudocellulite” = EF clues
• ❌ Raynaud’s & nailfold capillary changes → SSc hallmark
• 🩸 MRI ≈ biopsy for diagnosis
• 💊 Tx: Pulse IV methylpred → PO taper + MMF ± IVIg
• ⏱ Delay > 6 mo → 14× poorer outcome

#ACR25 #RheumDerm #EosinophilicFasciitis #Scleroderma #ACRAmbassador #Rheumatology #SkinInTheGame

[Roxana González @RoxOsler]

#ReviewCourse #ACR25 MAS treatment:
🔹Corticosteroids remain first-line
🔹 Anakinra (anti-IL1) improve survival in severe MAS
🔹 Emapalumab (anti-IFNγ) 93% remission in refractory cases; FDA-approved for steroid-refractory Still’s-MAS

[Roxana González @RoxOsler]

#ReviewCourse #ACR25 vasculitides & CNS involvement
🔹 Takayasu,PAN & ANCA-associated: CNS dysfunction rare but life-threatening.
🔹 GCA/PMR:overlapping inflammatory spectrum.
🔹 Behçet’s: parenchymal vs. cerebral venous thrombosis forms.
💊 Therapy: cyclophosphamide or TNF/IL-6

[Nelly ZIADE 🍀 @Nellziade]

🧯How to treat Macrophage Activation Syndrome in 2025

🔴Take-home points from Dr Nigrovic's talk on Still's Disease
1- Methylprednisolone + Anakinra
2- + Ruxolitinib
+/- Tacrolimnus / IVIG / Rituximab
3- Emapalumab
4- Etoposide + Dexamethasone

#ACR25
#GlobalSummit

[Rheumatology & Rheumatology Advances in Practice @RheumJnl]

New systematic review by @sinisauksav et al. characterises the complete phenotypic spectrum of VEXAS syndrome.

➡️These findings will facilitate earlier diagnosis, inform monitoring strategies, and guide future research priorities.

➡️https://t.co/YBEgKzWg4Z

[Nelly ZIADE 🍀 @Nellziade]

Comparison of the Definitions of the Complex to Manage -by GRAPPA- and Difficult to Manage -by EULAR- #Psoriatic_Arthritis
As presented at #EULAR2025 by Dr Fabian Proft OP0175 & Dr Helena Marzo-Ortega at the recommendations session
Two Frameworks for One Challenge

@RheumNow

[Dr. John Cush @RheumNow]

EULAR Classification criteria for hemachromatosis, presented by Prof. Kiely shows clinical pearls in diagnosis - Hook osteophytes @MCP 2/3, & Iron Fist sign w/ elevation of MCPs 2&3. #EULAR2025

[Rheuma Doc @LastManStand85]

New #EULAR clasificstion for Anti-Synthetase Syndrome [ASyS] #Rheumatology #MedTwitter #Myositis

[Nelly ZIADE 🍀 @Nellziade]

What's the difference between PIPsA & NIPsA?

(Persistent Inflammatory confirmed by IMAGING
vs. Non inflammatory PsA)

🔹️Cross-sectional study
🔹️517 pts under b/tsDMARDs
🔹️10.3% D2T
🔹️57% PIPsA / 43% NIPsA

👇 Distinct phenotypes 👇

OP0176
#EULAR2025
@rheumnow

[Rheuma Doc @LastManStand85]

Recommendations for #SLE with kidney involvement
NEW #EULAR2025 for #LupusNephritis
✅early renal biopsy
✅early combination therapy
✅non-immune treatment

[Antoni Chan MD (Prof) @synovialjoints]

Prédiction of PsA from PsO. Stockholm cohort, n=672):
•PsA incidence 21.1/1000 PY.
•AUC 0.80 for both referral and prognostic models.
•Predictors: HLA-B27, uveitis, enthesial pain, TJC, hsCRP, BMI, SAA, GlycA.
•Early identification feasible.

Abstract OP0178 @RheumNow #EULAR2025

[Janet Pope @Janetbirdope]

#neuromodulation in #rheumatoid #arthritis

What is it?
👇
Autonomic & immune system interaction

Who seeks this Rx?
desperate pts w pain
No Rx left
Interested in technology

#EULAR2025 @RheumNow @eular_org
#D2T #RA

[Md Yuzaiful Md Yusof @Yuz6Yusof]

#EULAR2025 Abstr#OP0199 Validation of effective & safe HCQ blood levels monitoring (750-1150ng/mL) to guide optimal dose. Particulary important in those with CKD Stage =>3 as considered high risk of toxicity. Next steps: wider availability & cost-effectiveness analysis @RheumNow

[Dott. Simone Parisi @Sim_Orizon]

🚨 Mind-blowing insights from Georg Schett at #EULAR2025:
CAR-T in autoimmune diseases is no longer experimental — it’s revolutionizing care.
✅ Immune reset → drug-free remission
✅ Efficacy in highly-resistant AID
✅ Allogenic & “armed” #CAR_T moving fast into clinics

[Alberto Giraldo @alb_giraldo]

Recommendations for pharmacologic treatment of rheumatoid arthritis-associated interstitial lung disease in the 2023 ACR/CHEST guideline

#Rheumatology #RheumatoidArthritis #InterstitialLungDisease #DMARDs #Antifibrotics

*From: Saavedra, A.A., Mueller, K.T., Kowalski, E.N. et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline. Curr Treat Options in Rheum 10, 43–60 (2024).
🔗https://t.co/UqGRBdAjcf

[Janet Pope @Janetbirdope]

If high +ANA and NO #rheumatic #disease

LOOK 👀 at #LIVER

#Autoimmune #hepatitis
And
#alcoholic #liver #dx

#ACRBest #ACR24 @rheumnow abst#0627